



UNIVERSITY OF LEEDS

This is a repository copy of *Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/109312/>

Version: Supplemental Material

Article:

Bell, R, Brown, JM orcid.org/0000-0002-2719-7064, Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760. ISSN 0923-7534

<https://doi.org/10.1093/annonc/mdw665>

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Annals of Oncology* following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: <https://doi.org/10.1093/annonc/mdw665>.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary Table S3. Grade ≥ 3 adverse events of special interest by treatment arm occurring between 18 months after the first dose of study drug and the end of the study

Adverse event of special interest	Chemotherapy alone (N = 1271)	Chemotherapy + bevacizumab (N = 1288)
Any event, N (%)	9 (0.7)	9 (0.7)
Arterial thromboembolic event, N (%)	1 (0.1) ^a	5 (0.4) ^b
Venous thromboembolic event, N (%)	3 (0.2) ^c	0
Bleeding, N (%)	1 (0.1) ^d	3 (0.2) ^e
Congestive heart failure, N (%)	0	1 (0.1) ^f
Hypertension, N (%)	4 (0.3) ^g	0
Proteinuria, N (%)	0	0
Wound-healing complication, N (%)	0	2 (0.2) ^h
RPLS, N (%)	0	0

Gastrointestinal perforation, N (%)	0	0
Fistula/abscess, N (%)	0	0
Febrile neutropenia, N (%)	0	0

^aGrade 3 myocardial infarction.

^bGrade 3 myocardial infarction (N = 1), grade 4 myocardial infarction (N = 1), grade 4 acute myocardial infarction (N = 1), grade 5 cerebrovascular accident (N = 1; the same event is also reported within the category 'Bleeding'), grade 3 transient ischemic attack (N = 1).

^cGrade 3 deep vein thrombosis (N = 3).

^dGrade 3 dysfunctional uterine bleeding.

^eGrade 5 cerebrovascular accident (N = 1; the same event is also reported within the category 'Arterial thromboembolic event'), grade 2/3 diverticulitis intestinal hemorrhagic (N = 1; repeated grade 2 and one grade 3 episode, attributed to ongoing colonic diverticulitis), grade 4 hematoma (N = 1).

^fGrade 3 cardiac failure congestive.

^gGrade 3 hypertension (N = 4)

^hGrade 3 wound caused by a traffic accident (N = 1), grade 3 wound abscess (N = 1).

In each patient, the adverse event occurred before any reported IDFS event, or in the case of the grade 5 cerebrovascular event, was itself the IDFS event.

IDFS, invasive disease-free survival; RPLS, **reversible posterior**
leukoencephalopathy syndrome.
